Karnataka sets 1 November drug-price disclosure rule; UAE clinics should audit pharmacy billing

Karnataka will require hospitals and laboratories to disclose medicine purchase prices and selling prices from 1 November 2026, a move that gives UAE clinics, insurers and pharmacy operators a live policy test to watch.

The rule was announced by U T Khader, Karnataka’s Health and Family Welfare Minister, according to Coastal Digest on 10 October 2026. It is an Indian state measure, not a UAE requirement. Its relevance for Dubai and Abu Dhabi is operational. A price-disclosure rule would hit three UAE desks first: the CFO tracking pharmacy margin, the COO responsible for invoice controls, and the insurer team checking direct-billing claims.

What Karnataka is asking hospitals to disclose

Khader said hospitals and laboratories covered by the rule must make medicine pricing information available to patients, with the purchase price and maximum retail price shown in bills. He linked the decision to complaints about overcharging, including during high-cost cancer treatment.

“Patients must know the price at which medicines are purchased and the price at which they are sold,” U T Khader, Karnataka Health and Family Welfare Minister, said.

The disclosure model is simple. It separates acquisition cost, billed price and statutory maximum retail price. For UAE providers, the closest parallel is the need to reconcile pharmacy procurement, payer billing and patient receipts inside one audit trail. That matters in Dubai, where the Dubai Health Authority (DHA) regulates licensed healthcare facilities, and in Abu Dhabi, where the Department of Health Abu Dhabi (DOH) supervises the market. In Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, the relevant health regulator is the Ministry of Health and Prevention (MOHAP).

Why UAE operators should pay attention

The UAE already has medicine-registration and price-reference infrastructure. MOHAP lists registered medicines through its registered medications list. The Emirates Drug Establishment also runs a registered medical product directory that shows registered products by name, classification, strength, form, manufacturer, country of origin and status. MOHAP guidance says clients can request a price list of UAE-registered medicines for AED 500.

For a clinic CFO, the practical question is whether the billed patient price can be traced back to the approved product and the supplier invoice. For a COO, the issue is whether the invoice can show a clear line item for the medicine, strength, quantity, pack size and payer adjustment. For a CIO, the test is whether the pharmacy system, revenue-cycle system and eClaims workflow use the same product identifier.

• Dubai clinics: map pharmacy billing controls to DHA licensing and audit files, including purchase invoices kept by the pharmacy.
• Abu Dhabi providers: test whether DOH-regulated claims can be reconciled against insurer approvals and medicine master data.
• Northern Emirates operators: use MOHAP registration data before adding medicines to formularies or cash-price lists.
• Insurers: compare pharmacy direct-billing rules across networks run by Daman, Thiqa and Sukoon where those plans apply.

The patient impact is also immediate. Cash-paying patients in the UAE already compare medicine prices through pharmacy apps, hospital receipts and government directories. A provider that cannot explain the difference between acquisition cost, payer rate and patient co-payment will face more disputes when high-cost oncology, diabetes, fertility or biologic medicines are involved.

What to audit before 2027 budgets close

UAE operators do not need to wait for a local disclosure mandate. A 30-day internal review can identify the risk. Start with the top 20 medicines by gross billed value in 2026. Pull the supplier invoice, approved UAE registration record, patient invoice and insurer remittance advice for each item. Any mismatch in product name, strength, pack size or billed quantity should be corrected before new payer contracts are signed.

The second check is patient-facing documentation. If the receipt says only “pharmacy item” or “medicine charge”, it will be weak evidence in a dispute. A better receipt gives the brand or generic name, dosage form, strength, quantity, co-payment and insurer approval status. Where a public UAE price cannot be confirmed, staff should know how to check the MOHAP or Emirates Drug Establishment directory rather than quoting an informal price.

The Karnataka rule starts on 1 November 2026. Its main lesson for the UAE is narrower than price control: medicine billing is becoming a transparency issue. Providers should review licensed pharmacy partners and competitors through the UAE Open Healthcare Directory, which lists UAE-licensed healthcare providers, including pharmacy providers across all seven emirates.